Table 2.
Comparison of the adverse events and therapeutic duration in patients with DHIC and OAB after 100 U onabotulinumtoxinA injection.
| Adverse Events | DHIC (n = 21) | OAB (n = 21) | p Value |
|---|---|---|---|
| AUR | 7 (33.3%) | 3 (14.3%) | 0.277 |
| PVR volume > 200 mL | 12 (57.1%) | 7 (33.3%) | 0.215 |
| UTI | 8 (38.1%) | 4 (19.0%) | 0.306 |
| Gross hematuria | 0 (0%) | 1 (4.8%) | 1.000 |
| General weakness | 1 (4.8%) | 0 (0%) | 1.000 |
| Therapeutic duration (months) | 4.9 ± 4.8 | 7.2 ± 3.3 | 0.03 |
DHIC: detrusor hyperactivity and impaired contractility; OAB: overactive bladder; AUR: acute urinary retention; PVR: post-void residual volume; UTI: urinary tract infection.